Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatmentSAN DIEGO, June 26, 2026 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused…

Read the full release →

News provided by PR Newswire.